Cancer and Leukemia Group B

$454,439U10FY2013CANIH

Dana-Farber Cancer Inst, Boston MA

Investigators

Linked publications & trials

Paper 37262321 Paper 35191970 Paper 33654204 Paper 31802506 Paper 31413100 Paper 30146695 Paper 29872168 Paper 29358223 Paper 29233548 Paper 29138761 Paper 29034366 Paper 28976791 Paper 28826616 Paper 28825227 Paper 28750659 Paper 28687377 Paper 28653250 Paper 28644114 Paper 28620884 Paper 28364214 Paper 28321123 Paper 28283904 Paper 28208174 Paper 27992272 Paper 27866278 Paper 26969090 Paper 26926677 Paper 26892479 Paper 26282659 Paper 26114161 Paper 25589620 Paper 25575253 Paper 25520391 Paper 25499481 Paper 25384173 Paper 25369488 Paper 25163570 Paper 24996441 Paper 24958280 Paper 24934787 Paper 24859205 Paper 24590644 Paper 24584876 Paper 24428673 Paper 24419419 Paper 24382782 Paper 24231454 Paper 24097873 Paper 24035029 Paper 23922187 Paper 23913744 Paper 23890224 Paper 23768804 Paper 23700288 Paper 23225546 Paper 23160462 Paper 23129738 Paper 23026566 Paper 22915637 Paper 22878823 Paper 22826271 Paper 22767584 Paper 22744771 Paper 22547605 Paper 22535500 Paper 22421007 Paper 22197613 Paper 22180287 Paper 22147942 Paper 22104618 Paper 22021121 Paper 21933890 Paper 21849660 Paper 21803850 Paper 21747089 Paper 21713765 Paper 21699879 Paper 21693770 Paper 21693655 Paper 21656739 Paper 21357782 Paper 21355087 Paper 21321569 Paper 21300923 Paper 21275630 Paper 21148613 Paper 20871263 Paper 20862750 Paper 20736856 Paper 20735398 Paper 20688393 Paper 20606091 Paper 20554945 Paper 20522709 Paper 20521348 Paper 20423913 Paper 20368559 Paper 20150438 Paper 20124181 Paper 20087228

Abstract

The Dana-Farber Cancer Institute (DFCI) and Dana-Farber/Partners CancerCare (DF/PCC) proposes to use its membership in the Cancer and Leukemia Group B (CALGB) to support participation in therapeautic research and other clinical trials, both in the Institute and its affiliate institutions. The goals of this project will be the initiation and participation in Phase I, II and III cooperative clinical trials involving chemotherapy, surgery and radiation therapy. A major emphasis will be made in developing new therapeutic strategies both at DFCI, MGH and in pilot collaborative investigations with interested membersof CALGB. Dana-Farber investigators would continue to be actively involved in disease and modality committees of the CALGB. This project is designed to bring cooperative group trials to regional community hospitals affilaitedthrough the Dana-Farber Cancer Institute throughout New England.

View original record on NIH RePORTER →